The purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
2 Capsules 3 times a day for 3 months
King Edward Medical University
Lahore, Punjab Province, Pakistan
15% improvement in eGFR
eGFR of the patients shall be evaluated for at least 15% improvement
Time frame: 6 months
Safety - Adverse Effects of Drugs
Adverse Effects of the drugs
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.